Company stated after the phase 1 trial that they were after a 25% reduction of sIGF-I in phase 2. These results state that only half, those treated with 400mg, achieved on average a 26% reduction of sIGF-I. While the other half, those treated with 200mg, achieved on average no reduction of sIGF-I. So to me that means the total trial on average achieved a 13% reduction of sIGF-I, half of what the company was trying to achieve. Granted they have gained some important data to take into phase 3, but without a partner there is no phase 3.
Company stated after the phase 1 trial that they were after a...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $31.40K | 304.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 176487 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 125575 | 4 |
View Market Depth
| Last trade - 12.42pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |